ArticleFrontiers in pharmacology2022

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation.

Xiaoyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.